title: Antioxidant effect of nondigestible levan and its impact on cardiovascular disease and atherosclerosis.
abstract: Levan polysaccharide, a type of fructan, has been shown to favorably affect diabetes type 2 and hypercholesterolemia. Recent reports have indicated that excessive oxidative stress contributes to the development of atherosclerosis linked metabolic syndrome. The objective of this current study was to investigate the possible protection against oxidative stress linked atherosclerosis. A group of twenty four male rats was divided into four subgroups; a normal diet group (Control), normal rats received levan (L), a high-cholesterol diet group (Chol) and a high-cholesterol diet with 5% (w/w) levan group. After the treatment period, the plasma antioxidant enzymes and lipid profiles were determined. Our results show that treatment with levan positively changed plasma antioxidant enzyme activities by increasing superoxide dismutase (SOD) and catalase (CAT) by 40% and 28%, respectively, in heart. Similarly, the treatment of Chol fed groups with levan positively changed lipid profiles by decreasing total cholesterol, triglycerides and LDL-cholesterol by 50%, 38.33% and 64%, respectively. Thus may have potential antioxidant effects and could protect against oxidative stress linked atherosclerosis.
authors.affiliation: Biochemistry Laboratory, Faculty of Sciences of Sfax, Sfax, Tunisia. imenbiologie@yahoo.fr
authors.forename: Imen
authors.initials: I
authors.lastname: Dahech
authors.forename: Bahira
authors.initials: B
authors.lastname: Harrabi
authors.forename: Khaled
authors.initials: K
authors.lastname: Hamden
authors.forename: Abdelfattah
authors.initials: A
authors.lastname: Feki
authors.forename: Hafedh
authors.initials: H
authors.lastname: Mejdoub
authors.forename: Hafedh
authors.initials: H
authors.lastname: Belghith
authors.forename: Karima Srih
authors.initials: KS
authors.lastname: Belghith
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000494:pharmacology* / Q000627:therapeutic use; D001011:Aorta / Q000187:drug effects / Q000473:pathology; D050197:Atherosclerosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002374:Catalase / Q000378:metabolism; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004353:Drug Evaluation, Preclinical; D005630:Fructans / Q000494:pharmacology* / Q000627:therapeutic use; D015227:Lipid Peroxidation; D008297:Male; D009206:Myocardium / Q000201:enzymology; D018384:Oxidative Stress; D011135:Polysaccharides, Bacterial / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D013482:Superoxide Dismutase / Q000378:metabolism; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014280:Triglycerides / Q000097:blood
chemical_list: D000975:Antioxidants; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D005630:Fructans; D011135:Polysaccharides, Bacterial; D017392:Thiobarbituric Acid Reactive Substances; D014280:Triglycerides; C072599:levan; D002374:Catalase; D013482:Superoxide Dismutase